BeOne Medicines combines 36% revenue growth, a Piotroski F-Score of 9/9, a wide economic moat, and a Rule of 40 score of 51 with strong analyst conviction (54% upside consensus), but the stock is in a confirmed falling knife pattern with RSI at 22, a death cross in place, and BRUKINSA product concentration risk from a single revenue driver.
Thesis pillars
- Brukinsa Concentration Growth Engine↑Improving
- Wide Moat Compounder Quality→Stable
- Falling Knife Technical Setup↑Improving
- +1 more pillar — see the Why tab for full reasoning
BeOne Medicines Ltd. (ONC) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $314.02. At $374.47 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $314.02 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Thin upside margin: 4.1%.
BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK inhibitor approved in 77 markets, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in 51 markets. The company generated approximately $5.3 billion in total... Read more
Wait for pullback to $314.02. At $374.47 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $314.02 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Thin upside margin: 4.1%. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.00, quality 7.7/10, growth 9.9/10). Score 6.5/10, moderate confidence.
Passes 5/7 gates (positive momentum, no SEC red flags, earnings proximity 75d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-08-23Recent Developments — BeOne Medicines Ltd.
Latest news
- NEWS BeOne Medicines Targets Esophageal Cancer With New Tislelizumab Trial in Japan - TipRanks — TipRanks positive
- NEWS Lazard Asset Management LLC Buys 14,696 Shares of BeOne Medicines Ltd. - Sponsored ADR $ONC - MarketBeat — MarketBeat neutral
- NEWS ADAR1 Capital Management LLC Makes New Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC - MarketBeat — MarketBeat neutral
- NEWS BeOne Medicines (ONC) Could Be 25% Undervalued After Its $300 Million Hopewell Expansion - simplywall.st — simplywall.st positive
- NEWS BeOne Medicines (ONC) Receives FDA Priority Review for Tevimbra Treatment - GuruFocus — GuruFocus positive
Generated 2026-08-23T02:21:54Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductBRUKINSA10-K Item 1: 'total global revenue of approximately $5.3 billion ... BRUKINSA generated $3.9 billion in sales in 2025'
- MEDIUMGeographicChina10-K Item 1A: 'which could have a material adverse effect on our business, financial condition and results of operations in China'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $314.02. At $374.47 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $314.02 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Thin upside margin: 4.1%. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.00, quality 7.7/10, growth 9.9/10). Target $389.71 (+4.1%), stop $292.68 (−27.9%), A.R:R 0.3:1. Score 6.5/10, moderate confidence.
Take-profit target: $389.71 (+4.1% upside). Target $389.71 (+4.1%), stop $292.68 (−27.9%), A.R:R 0.3:1. Stop-loss: $292.68.
Concentration risk — Product: BRUKINSA; Thin upside margin: 4.1%; Near 52-week high (2.8% away).
BeOne Medicines Ltd. trades at a P/E of 67.2 (forward 36.4). TrendMatrix value score: 4.5/10. Verdict: Buy (Wait for Entry).
12 analysts cover ONC with a consensus score of 4.2/5. Average price target: $433.
What does BeOne Medicines Ltd. do?BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK...
BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK inhibitor approved in 77 markets, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in 51 markets. The company generated approximately $5.3 billion in total revenue in 2025, with BRUKINSA contributing $3.9 billion in sales, and employs nearly 12,000 people across research, clinical, and commercial operations.